NCT01520272|Completed
HPV Vaccine Effectiveness in Partially Vaccinated Girls in Uganda
Immunogenicity of Bivalent HPV Vaccine Among Partially Vaccinated Young Adolescent Girls in Uganda
Loading search results
Immunogenicity of Bivalent HPV Vaccine Among Partially Vaccinated Young Adolescent Girls in Uganda
Sponsor study identifier
Secondary identifiers
observational
376
1 country
1
Study Start
January 2, 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
June 28, 2017
Date type not reportedThis date has not been verified as actual or estimated.
Background: \- Cervical cancer is one of the leading causes of cancer death in women worldwide and in Uganda. It is caused by the human papillomavirus (HPV). A vaccine against HPV was offered for all 10-year-old girls in the Nakasongola district of Uganda from October 1, 2008, to October 31, 2009. The HPV vaccine requires three doses; however, some girls received only one or two doses. Researchers want to compare vaccine immunogenicity in girls who received all three doses with those who had only one or two doses. Objectives: \- To examine the immunogenicity (antibody levels) of girls in Uganda who received only one, two or three doses of HPV vaccine. Eligibility:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 28, 2017
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2, 2012
Date type not reportedThis date has not been verified as actual or estimated.
January 26, 2012
Actual (reported)January 27, 2012
Actual (reported)June 28, 2017
Date type not reportedThis date has not been verified as actual or estimated.
HPV Immunogenicity
Ongoing
District of Nakasangola
Kampala, Uganda
Banura C, Mirembe FM, Katahoire AR, Namujju PB, Mbonye AK, Wabwire FM. Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review. Infect Agent Cancer. 2011 Jul 12;6(1):11. doi: 10.1186/1750-9378-6-11.
Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsague X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF Jr, Reisinger KS; Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006 Nov;118(5):2135-45. doi: 10.1542/peds.2006-0461.
Allan Hildesheim, Ph.D.
National Cancer Institute (NCI)
376 participants (actual enrollment reported by the registry).
First Submitted
January 26, 2012
First Posted
January 27, 2012
Study Start
January 2, 2012
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years --- United States, 2009. MMWR Morb Mortal Wkly Rep. 2010 Aug 20;59(32):1018-23.
Study Completion
June 28, 2017
Date type not reportedThis date has not been verified as actual or estimated.
Last Updated
April 5, 2018
Record last verified: 2017-06-28
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: